<DOC>
	<DOC>NCT00738582</DOC>
	<brief_summary>This research is being done to find out if pemetrexed and cisplatin work better when given together with an experimental drug called MORAb-009 in patients with malignant pleural mesothelioma.</brief_summary>
	<brief_title>An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma</brief_title>
	<detailed_description />
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Primary Confirmed diagnosis of malignant pleural mesothelioma (MPM) with the following characteristics: unresectable disease (or otherwise not a candidate for curative surgery); epithelial type or biphasic (mixed) type with low sarcomatous content. Measurable disease at Screening by computed tomography (CT)(or magnetic resonance imaging [MRI]). KPS of greater than or equal to 70% at Screening. Life expectancy of at least 3 months Primary Sarcomatous type of mesothelioma Prior systemic therapy or radiotherapy for MPM; local radiotherapy for symptom control (ie, noncurative intent) is permitted. Confirmed presence of CNS tumor involvement. Evidence of other active malignancy requiring treatment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>